| All Releases |
|---|
 |
Progenics Pharmaceuticals to Present at the BIO International Convention
Jun 15, 2012
|
17.2 KB
|
| |
TARRYTOWN, N.Y., June 15, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will present at the 2012 BIO International Convention's Business Forum, a unique venue where biotechnology companies, academic research institutions and investors intersect to review strategic opportunities. Mr. Bak...
|
|
|
Progenics Pharmaceuticals Announces First Quarter 2012 Financial Results
May 8, 2012
|
25.1 KB
|
| |
TARRYTOWN, N.Y., May 8, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31.
Net loss for the quarter was $13.1 million, or $0.39 basic and diluted per share, compared to a net loss of $22.9 million ($0.69 per share) in 2011, primarily due to a $10.0...
|
|
|
Progenics Pharmaceuticals to Host Conference Call to Review First Quarter Financial Results on May 8
May 4, 2012
|
14.0 KB
|
| |
TARRYTOWN, N.Y., May 4, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the first quarter on Tuesday, May 8, 2012 at 8:30 a.m. EDT.
To participate, please dial (877) 250-8889 (domestic) or (720) 545-0001 (international...
|
|
|
Salix and Progenics Announce FDA Extension of RELISTOR® sNDA Goal Date to July 27, 2012
Apr 25, 2012
|
12.7 KB
|
| |
RALEIGH, N.C.--(BUSINESS WIRE)--
Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals
(NASDAQ: PGNX) today announced that the Food and Drug Administration
(FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date
for the Agency's review of the Supplemental New Drug Application (s...
|
|
|
Progenics Pharmaceuticals to Participate in Investor Conferences
Mar 29, 2012
|
14.6 KB
|
| |
TARRYTOWN, N.Y., March 29, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) chief executive officer Mark R. Baker will present at two upcoming investor conferences in New York City:
11th Annual Needham Healthcare Conference
10:40 a.m. ET, Tuesday, April 3
19th Annual Future Leaders in the Bi...
|
|
|
Progenics Pharmaceuticals Announces Retirement of Founder Paul J. Maddon
Mar 15, 2012
|
20.4 KB
|
| |
TARRYTOWN, N.Y., March 15, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that company founder Paul J. Maddon, M.D., Ph.D. has retired as chief science officer of the company. He continues as a member and vice chair of the Progenics board of directors.
Progenics was founded by Dr. Maddon in 1986. He h...
|
|
|
Progenics Pharmaceuticals Announces Fourth Quarter and Year-End 2011 Financial Results
Mar 15, 2012
|
30.5 KB
|
| |
TARRYTOWN, N.Y., March 15, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the fourth quarter and year end 2011 results of operations.
Net loss for the quarter was $10.7 million or $0.32 diluted per share, compared to a net loss of $18.8 million or $0.57 diluted per share in the fourth quarter of 2010....
|
|
|
Progenics Pharmaceuticals to Host Conference Call to Review Fourth Quarter and Year-End 2011 Financial Results on March 15
Mar 13, 2012
|
17.1 KB
|
| |
TARRYTOWN, N.Y., March 13, 2012 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the fourth quarter and year-end 2011 on Thursday, March 15, 2012 at 8:30 a.m. EDT.
To participate, please dial (877) 250-8889 (domestic) or (72...
|
|
|
Salix and Progenics Announce Positive Highly Statistically Significant Results of Oral Methylnaltrexone for Phase 3 Trial in Chronic, Non-Cancer Pain Subjects with Opioid-Induced Constipation
Dec 20, 2011
|
18.2 KB
|
| |
NDA Submission Targeted for Mid 2012
RALEIGH, N.C. & TARRYTOWN, N.Y.--(BUSINESS WIRE)--
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) and Progenics Pharmaceuticals,
Inc. (NASDAQ:PGNX) today announced the successful outcome of the Phase 3
trial to evaluate the efficacy and safety of oral methylna...
|
|
|
Progenics Pharmaceuticals Announces Third Quarter 2011 Financial Results
Nov 9, 2011
|
33.2 KB
|
| |
TARRYTOWN, N.Y., Nov. 9, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced third quarter 2011 results of operations.
"We have been pleased by the efforts of our partner Salix during this second quarter commercializing RELISTOR," said Mark R. Baker, Progenics' chief executive officer. "We look forward to ...
|
|
|
Progenics Pharmaceuticals to Participate in Investor Conferences
Nov 8, 2011
|
19.0 KB
|
| |
TARRYTOWN, N.Y., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at two upcoming investor conferences in New York City:
Brean Murray, Carret & Co. 2011 Life Sciences Summit beginning at 8:00 a.m. Eastern Time on Monday, November 14
8th Annual Lazard ...
|
|
|
Progenics to Host Conference Call to Review Third Quarter 2011 Financial Results on November 9
Nov 3, 2011
|
18.5 KB
|
| |
TARRYTOWN, N.Y., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) will host a conference call and webcast to discuss its financial results for the third quarter of 2011 on Wednesday, November 9, 2011 at 8:30 a.m. Eastern Time.
To join the conference call, please dial 877-250-8889 (domestic) or 720-545-0001 (int...
|
|
|
Progenics Pharmaceuticals to Present at NewsMakers Conference
Oct 14, 2011
|
17.8 KB
|
| |
TARRYTOWN, N.Y., Oct. 14, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. Chief Executive Officer Mark R. Baker will present at the 18th Annual "NewsMakers in the Biotech Industry" conference sponsored by BioCentury and Thomson Reuters on Friday, October 21st in New York City. The 3:00 p.m. Eastern time presentation will be webcast live on...
|
|
|
Progenics Pharmaceuticals to Present at UBS Global Life Sciences Conference
Sep 16, 2011
|
18.3 KB
|
| |
TARRYTOWN, N.Y., Sept. 16, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that Chief Executive Officer Mark R. Baker will present at the UBS Global Life Sciences Conference on Monday, September 19 at 9:00 a.m. EDT. The presentation will be webcast live and will be archived for 30 days on the Events page of Pr...
|
|
|
Progenics Pharmaceuticals Announces Strategic Focus on Oncology
Sep 15, 2011
|
25.5 KB
|
| |
— Highlights actions resulting from strategic review —
— Conference call and webcast today at 8:30 a.m. ET —
TARRYTOWN, N.Y., Sept. 15, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced strategic, operational, organizational and financial changes resulting from a review ...
|
|
|
Progenics and Salix Announce FDA Acceptance of sNDA Filing for RELISTOR® in Patients with Non-Cancer Pain
Aug 30, 2011
|
18.1 KB
|
| |
— PDUFA Action Date is April 27, 2012 —
TARRYTOWN, N.Y. & RALEIGH, N.C.--(BUSINESS WIRE)--
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) and Salix Pharmaceuticals,
Ltd. (NASDAQ:SLXP) today announced that the U.S. Food and Drug
Administration (FDA) has accepted for filing a supple...
|
|
|
Progenics Pharmaceuticals Announces Second Quarter 2011 Financial Results
Aug 9, 2011
|
32.5 KB
|
| |
— Second quarter U.S. sales of RELISTOR® increased 99% over first quarter and 50% over prior year quarter —
— Enrollment in phase 3 trial of oral methylnaltrexone completed —
— Conference call and webcast at 8:30 am ET today —
TARRYTOWN, N.Y., Aug. 9, 2011 (GLOBE NEWSWIRE) -- Progeni...
|
|
|
Progenics to Host Conference Call to Review Second Quarter 2011 Financial Results on August 9
Aug 2, 2011
|
7.7 KB
|
| |
TARRYTOWN, N.Y., Aug. 2, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it will host a conference call and webcast to discuss its financial results for the second quarter of 2011 on Tuesday, August 9, 2011 at 8:30 a.m. ET.
To join the conference call, please dial 877-250-8889 (domestic) or 720...
|
|
|
Progenics Submits RELISTOR(R) Supplemental NDA for the Treatment of Opioid-Induced Constipation in Patients With Chronic, Non-Cancer Pain
Jun 28, 2011
|
20.9 KB
|
| |
TARRYTOWN, N.Y., June 28, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting approval for the use of RELISTOR® (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-i...
|
|
|
Progenics Pharmaceuticals to Present at Jefferies 2011 Global Healthcare Conference
Jun 2, 2011
|
19.8 KB
|
| |
TARRYTOWN, N.Y., June 2, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that Mark Baker, the Company's chief executive officer, will present a company update at the Jefferies 2011 Global Healthcare Conference in New York on Monday, June 6, 2011 at 10:30 a.m. ET.
The presentation will be available via ...
|
|
|
